{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T13:34:39Z","timestamp":1772804079653,"version":"3.50.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T00:00:00Z","timestamp":1734912000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T00:00:00Z","timestamp":1734912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"DOI":"10.1186\/s13195-024-01629-y","type":"journal-article","created":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T12:12:11Z","timestamp":1734955931000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Data-driven CSF biomarker profiling: imaging and clinical outcomes in a cohort at risk of Alzheimer\u2019s disease"],"prefix":"10.1186","volume":"16","author":[{"given":"Georgette","family":"Argiris","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muge","family":"Akinci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cleof\u00e9","family":"Pe\u00f1a-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleni","family":"Palpatzis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Garcia-Prat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahnaz","family":"Shekari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gwendlyn","family":"Kollmorgen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara","family":"Quijano-Rubio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas J.","family":"Ashton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas K.","family":"Karikari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann","family":"Brinkmalm-Westman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Lantero-Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karine","family":"Fauria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gonzalo","family":"S\u00e1nchez-Benavides","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oriol","family":"Grau-Rivera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Su\u00e1rez-Calvet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eider M.","family":"Arenaza-Urquijo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"for the ALFA","family":"study","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,23]]},"reference":[{"issue":"4","key":"1629_CR1","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14(4):535\u201362.","journal-title":"Alzheimers Dement"},{"issue":"12","key":"1629_CR2","doi-asserted-by":"publisher","first-page":"175628641988881","DOI":"10.1177\/1756286419888819","volume":"18","author":"M Mil\u00e0-Alom\u00e0","year":"2019","unstructured":"Mil\u00e0-Alom\u00e0 M, Su\u00e1rez-Calvet M, Molinuevo JL. Latest advances in cerebrospinal fluid and blood biomarkers of Alzheimer\u2019s disease. Ther Adv Neurol Disord. 2019;18(12):1756286419888819.","journal-title":"Ther Adv Neurol Disord"},{"issue":"19","key":"1629_CR3","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2015.4668","volume":"313","author":"WJ Jansen","year":"2015","unstructured":"Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FRJ, et al. Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. JAMA. 2015;313(19):1924\u201338.","journal-title":"JAMA"},{"issue":"15","key":"1629_CR4","doi-asserted-by":"publisher","first-page":"e2065","DOI":"10.1212\/WNL.0000000000010527","volume":"95","author":"EM Arenaza-Urquijo","year":"2020","unstructured":"Arenaza-Urquijo EM, Salvad\u00f3 G, Operto G, Minguill\u00f3n C, S\u00e1nchez-Benavides G, Crous-Bou M, et al. Association of years to parent\u2019s sporadic onset and risk factors with neural integrity and Alzheimer biomarkers. Neurology. 2020;95(15):e2065\u201374.","journal-title":"Neurology"},{"issue":"5","key":"1629_CR5","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1001\/jamaneurol.2017.5135","volume":"75","author":"S Villeneuve","year":"2018","unstructured":"Villeneuve S, Vogel JW, Gonneaud J, Pichet Binette A, Rosa-Neto P, Gauthier S, et al. Proximity to Parental Symptom Onset and Amyloid-\u03b2 Burden in Sporadic Alzheimer Disease. JAMA Neurol. 2018;75(5):608\u201319.","journal-title":"JAMA Neurol"},{"issue":"2","key":"1629_CR6","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1212\/WNL.0000000000007747","volume":"93","author":"GN Bischof","year":"2019","unstructured":"Bischof GN, Jacobs HIL. Subthreshold amyloid and its biological and clinical meaning: Long way ahead. Neurology. 2019;93(2):72\u20139.","journal-title":"Neurology"},{"issue":"5","key":"1629_CR7","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1212\/WNL.0000000000000650","volume":"83","author":"SE Monsell","year":"2014","unstructured":"Monsell SE, Mock C, Hassenstab J, Roe CM, Cairns NJ, Morris JC, et al. Neuropsychological changes in asymptomatic persons with Alzheimer disease neuropathology. Neurology. 2014;83(5):434\u201340.","journal-title":"Neurology"},{"issue":"11","key":"1629_CR8","doi-asserted-by":"publisher","first-page":"4781","DOI":"10.1038\/s41380-022-01716-2","volume":"27","author":"JP Ferrari-Souza","year":"2022","unstructured":"Ferrari-Souza JP, Ferreira PCL, Bellaver B, Tissot C, Wang YT, Leffa DT, et al. Astrocyte biomarker signatures of amyloid-\u03b2 and tau pathologies in Alzheimer\u2019s disease. Mol Psychiatry. 2022;27(11):4781\u20139.","journal-title":"Mol Psychiatry"},{"key":"1629_CR9","doi-asserted-by":"crossref","unstructured":"Pelkmans W, Shekari M, Brugulat-Serrat A, S\u00e1nchez-Benavides G, Minguill\u00f3n C, Fauria K, et al. Astrocyte biomarkers GFAP and YKL-40 mediate early Alzheimer\u2019s disease progression. Alzheimers Dement. 2023.","DOI":"10.1002\/alz.13450"},{"issue":"3","key":"1629_CR10","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/alz.12204","volume":"17","author":"C Van Hulle","year":"2021","unstructured":"Van Hulle C, Jonaitis EM, Betthauser TJ, Batrla R, Wild N, Kollmorgen G, et al. An examination of a novel multipanel of CSF biomarkers in the Alzheimer\u2019s disease clinical and pathological continuum. Alzheimers Dement. 2021;17(3):431\u201345.","journal-title":"Alzheimers Dement"},{"key":"1629_CR11","unstructured":"Revised Criteria for Diagnosis and Staging of Alzheimer\u2019s | AAIC [Internet]. Revised Criteria for Diagnosis and Staging of Alzheimer\u2019s | AAIC. [cited 2024 Mar 20]. Available from: https:\/\/aaic.alz.org\/diagnostic-criteria.asp."},{"issue":"1","key":"1629_CR12","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13195-023-01168-y","volume":"15","author":"SC Johnson","year":"2023","unstructured":"Johnson SC, Su\u00e1rez-Calvet M, Suridjan I, Minguill\u00f3n C, Gispert JD, Jonaitis E, et al. Identifying clinically useful biomarkers in neurodegenerative disease through a collaborative approach: the NeuroToolKit. Alzheimers Res Ther. 2023;15(1):25.","journal-title":"Alzheimers Res Ther"},{"issue":"6","key":"1629_CR13","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s00401-014-1362-3","volume":"128","author":"CR Jack","year":"2014","unstructured":"Jack CR. PART and SNAP. Acta Neuropathol. 2014;128(6):773\u20136.","journal-title":"Acta Neuropathol"},{"issue":"2","key":"1629_CR14","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.trci.2016.02.003","volume":"2","author":"JL Molinuevo","year":"2016","unstructured":"Molinuevo JL, Gramunt N, Gispert JD, Fauria K, Esteller M, Minguillon C, et al. The ALFA project: A research platform to identify early pathophysiological features of Alzheimer\u2019s disease. Alzheimers Dement (N Y). 2016;2(2):82\u201392.","journal-title":"Alzheimers Dement (N Y)"},{"issue":"10","key":"1629_CR15","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1002\/alz.12131","volume":"16","author":"M Mil\u00e0-Alom\u00e0","year":"2020","unstructured":"Mil\u00e0-Alom\u00e0 M, Salvad\u00f3 G, Gispert JD, Vilor-Tejedor N, Grau-Rivera O, Sala-Vila A, et al. Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer\u2019s continuum. Alzheimers Dement. 2020;16(10):1358\u201371.","journal-title":"Alzheimers Dement"},{"issue":"12","key":"1629_CR16","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202012921","volume":"12","author":"M Su\u00e1rez-Calvet","year":"2020","unstructured":"Su\u00e1rez-Calvet M, Karikari TK, Ashton NJ, Lantero Rodr\u00edguez J, Mil\u00e0-Alom\u00e0 M, Gispert JD, et al. Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer\u2019s continuum when only subtle changes in A\u03b2 pathology are detected. EMBO Mol Med. 2020;12(12):e12921.","journal-title":"EMBO Mol Med"},{"issue":"21","key":"1629_CR17","doi-asserted-by":"publisher","first-page":"e2065","DOI":"10.1212\/WNL.0000000000012853","volume":"97","author":"M Mil\u00e0-Alom\u00e0","year":"2021","unstructured":"Mil\u00e0-Alom\u00e0 M, Brinkmalm A, Ashton NJ, Kvartsberg H, Shekari M, Operto G, et al. CSF Synaptic Biomarkers in the Preclinical Stage of Alzheimer Disease and Their Association With MRI and PET: A Cross-sectional Study. Neurology. 2021;97(21):e2065\u201378.","journal-title":"Neurology"},{"issue":"1","key":"1629_CR18","first-page":"68","volume":"8","author":"M Mil\u00e0-Alom\u00e0","year":"2021","unstructured":"Mil\u00e0-Alom\u00e0 M, Salvad\u00f3 G, Shekari M, Grau-Rivera O, Sala-Vila A, S\u00e1nchez-Benavides G, et al. Comparative Analysis of Different Definitions of Amyloid-\u03b2 Positivity to Detect Early Downstream Pathophysiological Alterations in Preclinical Alzheimer. J Prev Alzheimers Dis. 2021;8(1):68\u201377.","journal-title":"J Prev Alzheimers Dis"},{"key":"1629_CR19","doi-asserted-by":"crossref","unstructured":"Salvad\u00f3 G, Shekari M, Falcon C, Operto G, Mil\u00e0-Alom\u00e0 M, S\u00e1nchez-Benavides G, et al. Brain alterations in the early Alzheimer\u2019s continuum with amyloid-\u03b2, tau, glial and neurodegeneration CSF markers. Brain Communications. 2022;4(3):fcac134.","DOI":"10.1093\/braincomms\/fcac134"},{"issue":"1","key":"1629_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","volume":"11","author":"WE Klunk","year":"2015","unstructured":"Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD Sr, Jagust WJ, et al. The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET. Alzheimer\u2019s & Dementia. 2015;11(1):1-15.e4.","journal-title":"Alzheimer\u2019s & Dementia"},{"issue":"1","key":"1629_CR21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13195-019-0478-z","volume":"11","author":"G Salvad\u00f3","year":"2019","unstructured":"Salvad\u00f3 G, Molinuevo JL, Brugulat-Serrat A, Falcon C, Grau-Rivera O, Su\u00e1rez-Calvet M, et al. Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers. Alzheimers Res Ther. 2019;11(1):27.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"1629_CR22","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.neuroimage.2007.07.007","volume":"38","author":"J Ashburner","year":"2007","unstructured":"Ashburner J. A fast diffeomorphic image registration algorithm. Neuroimage. 2007;38(1):95\u2013113.","journal-title":"Neuroimage"},{"key":"1629_CR23","unstructured":"Reitan R, Reitan R. Trail Making Test: Manual for Administration and Scoring. In 1992 [cited 2023 Oct 16]. Available from: https:\/\/www.semanticscholar.org\/paper\/Trail-Making-Test%3A-Manual-for-Administration-and-Reitan-Reitan\/fb3612f133568883caa7c9c61e12d8cfe27807d3."},{"issue":"3","key":"1629_CR24","doi-asserted-by":"publisher","first-page":"613","DOI":"10.3233\/JAD-150237","volume":"48","author":"N Gramunt","year":"2015","unstructured":"Gramunt N, Buschke H, S\u00e1nchez-Benavides G, Lipton RB, Pe\u00f1a-Casanova J, Di\u00e9guez-Vide F, et al. Reference Data of the Spanish Memory Binding Test in a Midlife Population from the ALFA STUDY (Alzheimer\u2019s and Family). J Alzheimers Dis. 2015;48(3):613\u201325.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"1629_CR25","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/arclin\/acw083","volume":"32","author":"H Buschke","year":"2017","unstructured":"Buschke H, Mowrey WB, Ramratan WS, Zimmerman ME, Loewenstein DA, Katz MJ, et al. Memory Binding Test Distinguishes Amnestic Mild Cognitive Impairment and Dementia from Cognitively Normal Elderly. Arch Clin Neuropsychol. 2017;32(1):29\u201339.","journal-title":"Arch Clin Neuropsychol"},{"key":"1629_CR26","doi-asserted-by":"crossref","unstructured":"Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 1997;278(16):1349\u201356.","DOI":"10.1001\/jama.278.16.1349"},{"issue":"13","key":"1629_CR27","doi-asserted-by":"publisher","first-page":"5949","DOI":"10.1073\/pnas.0914141107","volume":"107","author":"L Mosconi","year":"2010","unstructured":"Mosconi L, Rinne JO, Tsui WH, Berti V, Li Y, Wang H, et al. Increased fibrillar amyloid-{beta} burden in normal individuals with a family history of late-onset Alzheimer\u2019s. Proc Natl Acad Sci U S A. 2010;107(13):5949\u201354.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"1629_CR28","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1212\/WNL.0000000000002923","volume":"87","author":"CR Jack","year":"2016","unstructured":"Jack CR, Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB, et al. A\/T\/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016;87(5):539\u201347.","journal-title":"Neurology"},{"key":"1629_CR29","doi-asserted-by":"crossref","unstructured":"K\u00e4rkk\u00e4inen M, Prakash M, Zare M, Tohka J, For The Alzheimer\u2019s Disease Neuroimaging Initiative null. Structural Brain Imaging Phenotypes of Mild Cognitive Impairment (MCI) and Alzheimer\u2019s Disease (AD) Found by Hierarchical Clustering. Int J Alzheimers Dis. 2020;2020:2142854.","DOI":"10.1155\/2020\/2142854"},{"key":"1629_CR30","doi-asserted-by":"crossref","unstructured":"Hern\u00e1ndez-Lorenzo L, Gil-Moreno MJ, Ortega-Madue\u00f1o I, C\u00e1rdenas MC, Diez-Cirarda M, Delgado-\u00c1lvarez A, et al. A data-driven approach to complement the A\/T\/(N) classification system using CSF biomarkers. CNS Neurosci Ther. 2023.","DOI":"10.1111\/cns.14382"},{"issue":"3","key":"1629_CR31","first-page":"735","volume":"140","author":"A Dong","year":"2017","unstructured":"Dong A, Toledo JB, Honnorat N, Doshi J, Varol E, Sotiras A, et al. Heterogeneity of neuroanatomical patterns in prodromal Alzheimer\u2019s disease: links to cognition, progression and biomarkers. Brain. 2017;140(3):735\u201347.","journal-title":"Brain"},{"issue":"1","key":"1629_CR32","doi-asserted-by":"publisher","first-page":"6763","DOI":"10.1038\/s41598-017-06624-y","volume":"7","author":"D Gamberger","year":"2017","unstructured":"Gamberger D, Lavra\u010d N, Srivatsa S, Tanzi RE, Doraiswamy PM. Identification of clusters of rapid and slow decliners among subjects at risk for Alzheimer\u2019s disease. Sci Rep. 2017;7(1):6763.","journal-title":"Sci Rep"},{"key":"1629_CR33","doi-asserted-by":"crossref","unstructured":"Ritchie C, Smailagic N, Noel-Storr AH, Ukoumunne O, Ladds EC, Martin S. CSF tau and the CSF tau\/ABeta ratio for the diagnosis of Alzheimer\u2019s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev. 2017;3(3):CD010803.","DOI":"10.1002\/14651858.CD010803.pub2"},{"issue":"4","key":"1629_CR34","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","volume":"14","author":"MT Heneka","year":"2015","unstructured":"Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, et al. Neuroinflammation in Alzheimer\u2019s Disease. Lancet Neurol. 2015;14(4):388\u2013405.","journal-title":"Lancet Neurol"},{"issue":"9","key":"1629_CR35","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202012308","volume":"12","author":"M Ewers","year":"2020","unstructured":"Ewers M, Biechele G, Su\u00e1rez-Calvet M, Sacher C, Blume T, Morenas-Rodriguez E, et al. Higher CSF sTREM2 and microglia activation are associated with slower rates of beta-amyloid accumulation. EMBO Mol Med. 2020;12(9): e12308.","journal-title":"EMBO Mol Med"},{"key":"1629_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2019.101786","volume":"22","author":"E Dicks","year":"2019","unstructured":"Dicks E, Vermunt L, van der Flier WM, Visser PJ, Barkhof F, Scheltens P, et al. Modeling grey matter atrophy as a function of time, aging or cognitive decline show different anatomical patterns in Alzheimer\u2019s disease. Neuroimage Clin. 2019;22: 101786.","journal-title":"Neuroimage Clin"},{"issue":"2","key":"1629_CR37","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","volume":"12","author":"CR Jack","year":"2013","unstructured":"Jack CR, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Update on hypothetical model of Alzheimer\u2019s disease biomarkers. Lancet Neurol. 2013;12(2):207\u201316.","journal-title":"Lancet Neurol"},{"issue":"1","key":"1629_CR38","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S0197-4580(99)00107-4","volume":"21","author":"A Convit","year":"2000","unstructured":"Convit A, de Asis J, de Leon MJ, Tarshish CY, De Santi S, Rusinek H. Atrophy of the medial occipitotemporal, inferior, and middle temporal gyri in non-demented elderly predict decline to Alzheimer\u2019s disease. Neurobiol Aging. 2000;21(1):19\u201326.","journal-title":"Neurobiol Aging"},{"issue":"220","key":"1629_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2020.116991","volume":"15","author":"MR Scott","year":"2020","unstructured":"Scott MR, Hampton OL, Buckley RF, Chhatwal JP, Hanseeuw BJ, Jacobs HI, et al. Inferior temporal tau is associated with accelerated prospective cortical thinning in clinically normal older adults. Neuroimage. 2020;15(220): 116991.","journal-title":"Neuroimage"},{"issue":"1","key":"1629_CR40","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13195-019-0471-6","volume":"11","author":"OA Halawa","year":"2019","unstructured":"Halawa OA, Gatchel JR, Amariglio RE, Rentz DM, Sperling RA, Johnson KA, et al. Inferior and medial temporal tau and cortical amyloid are associated with daily functional impairment in Alzheimer\u2019s disease. Alzheimers Res Ther. 2019;11(1):14.","journal-title":"Alzheimers Res Ther"},{"issue":"3","key":"1629_CR41","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jalz.2016.08.005","volume":"13","author":"CR Jack","year":"2017","unstructured":"Jack CR, Wiste HJ, Weigand SD, Therneau TM, Lowe VJ, Knopman DS, et al. Defining imaging biomarker cut-points for brain aging and Alzheimer\u2019s disease. Alzheimers Dement. 2017;13(3):205\u201316.","journal-title":"Alzheimers Dement"},{"issue":"9","key":"1629_CR42","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1093\/cercor\/bhn232","volume":"19","author":"AM Fjell","year":"2009","unstructured":"Fjell AM, Westlye LT, Amlien I, Espeseth T, Reinvang I, Raz N, et al. High consistency of regional cortical thinning in aging across multiple samples. Cereb Cortex. 2009;19(9):2001\u201312.","journal-title":"Cereb Cortex"},{"issue":"76","key":"1629_CR43","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.neuroimage.2013.02.059","volume":"1","author":"A Bakkour","year":"2013","unstructured":"Bakkour A, Morris JC, Wolk DA, Dickerson BC. The effects of aging and Alzheimer\u2019s disease on cerebral cortical anatomy: Specificity and differential relationships with cognition. Neuroimage. 2013;1(76):332\u201344.","journal-title":"Neuroimage"},{"issue":"2","key":"1629_CR44","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S1053-8119(02)00026-5","volume":"18","author":"G Chetelat","year":"2003","unstructured":"Chetelat G, Baron JC. Early diagnosis of Alzheimer\u2019s disease: contribution of structural neuroimaging. Neuroimage. 2003;18(2):525\u201341.","journal-title":"Neuroimage"},{"issue":"7","key":"1629_CR45","first-page":"933","volume":"12","author":"E Da Cunha","year":"2022","unstructured":"Da Cunha E, Plonka A, Arslan S, Mouton A, Meyer T, Robert P, et al. Logogenic Primary Progressive Aphasia or Alzheimer Disease: Contribution of Acoustic Markers in Early Differential Diagnosis. Life (Basel). 2022;12(7):933.","journal-title":"Life (Basel)"},{"issue":"3","key":"1629_CR46","doi-asserted-by":"publisher","first-page":"fcab125","DOI":"10.1093\/braincomms\/fcab125","volume":"3","author":"DD Jobson","year":"2021","unstructured":"Jobson DD, Hase Y, Clarkson AN, Kalaria RN. The role of the medial prefrontal cortex in cognition, ageing and dementia. Brain Commun. 2021;3(3):fcab125.","journal-title":"Brain Commun"},{"issue":"3","key":"1629_CR47","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):270\u20139.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"1629_CR48","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1017\/S1355617709090626","volume":"15","author":"I S\u00e1nchez-Cubillo","year":"2009","unstructured":"S\u00e1nchez-Cubillo I, Peri\u00e1\u00f1ez JA, Adrover-Roig D, Rodr\u00edguez-S\u00e1nchez JM, R\u00edos-Lago M, Tirapu J, et al. Construct validity of the Trail Making Test: role of task-switching, working memory, inhibition\/interference control, and visuomotor abilities. J Int Neuropsychol Soc. 2009;15(3):438\u201350.","journal-title":"J Int Neuropsychol Soc"},{"issue":"15","key":"1629_CR49","doi-asserted-by":"publisher","first-page":"e1525","DOI":"10.1212\/WNL.0000000000013299","volume":"98","author":"P Tideman","year":"2022","unstructured":"Tideman P, Stomrud E, Leuzy A, Mattsson-Carlgren N, Palmqvist S, Hansson O, et al. Association of \u03b2-Amyloid Accumulation With Executive Function in Adults With Unimpaired Cognition. Neurology. 2022;98(15):e1525\u201333.","journal-title":"Neurology"},{"issue":"6","key":"1629_CR50","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/ana.22628","volume":"71","author":"CR Jack","year":"2012","unstructured":"Jack CR, Knopman DS, Weigand SD, Wiste HJ, Vemuri P, Lowe V, et al. An operational approach to National Institute on Aging-Alzheimer\u2019s Association criteria for preclinical Alzheimer disease. Ann Neurol. 2012;71(6):765\u201375.","journal-title":"Ann Neurol"},{"key":"1629_CR51","doi-asserted-by":"crossref","unstructured":"Idland AV, Sala-Llonch R, Watne LO, Br\u00e6khus A, Hansson O, Blennow K, et al. Biomarker profiling beyond amyloid and tau: cerebrospinal fluid markers, hippocampal atrophy, and memory change in cognitively unimpaired older adults. Neurobiol Aging. 2020;93:1\u201315.","DOI":"10.1016\/j.neurobiolaging.2020.04.002"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-024-01629-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-024-01629-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-024-01629-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T13:05:45Z","timestamp":1734959145000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-024-01629-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,23]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1629"],"URL":"https:\/\/doi.org\/10.1186\/s13195-024-01629-y","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,23]]},"assertion":[{"value":"28 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The ALFA\u2009+\u2009study (ALFA-FPM-0311) was approved by the Independent Ethics Committee \u201cParc de Salut Mar,\u201d Barcelona, and registered at Clinicaltrials.gov\u00a0(identifier:\u00a0NCT02485730) on June 10, 2015. All participants signed the informed consent form that had also been approved by the Independent Ethics Committee \u201cParc de Salut Mar,\u201d Barcelona. The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments and comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"NA.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"H.Z. has served at scientific advisory boards and\/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). G.K. is a full\u2011time employee of Roche Diagnostics GmbH. C.Q.-R. is a full\u2011time employee of Roche Diagnostics International Ltd. O.G-R. has given lectures in symposia sponsored by Roche Diagnostics, and receives support for research (to the institution) from F- Hoffmann La Roche. M.S.-C. has given lectures in symposia sponsored by Roche Diagnostics, S.L.U, Roche Farma, S.A and Amirall. He has served as a consultant and at advisory boards for Roche Diagnostics International Ltd and Grifols S.L. He was granted with a project funded by Roche Diagnostics International Ltd; payments were made to the institution (BBRC). He received in-kind support for research (to the institution) from Roche Diagnostics International Ltd, Avid Radiopharmaceuticals, Inc., Eli Lilly and Janssen Research & Development.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"274"}}